openPR Logo
Press release

EGFR Mutation Test Market Estimated to Flourish by 2016 – 2024

07-06-2017 03:48 PM CET | Health & Medicine

Press release from: Persistence Market Research

EGFR Mutation Test Market Estimated to Flourish by 2016 – 2024

Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.

Lung cancer is a significant economic burden and is one of the major causes of mortality. According to World Health Organization (WHO), lung cancer is the most common form of cancer in males, with a worldwide incidence of 1.2 Mn. It is also the fourth most common cancer in women, with an incidence of over 0.6 Mn. Lung cancer is estimated to account for 20% of all the cancer-related deaths.

Increasing global prevalence of lung cancer is expected to fuel growth of the global EGFR mutation test market over the forecast period. Increasing adoption of biomarker therapy is also expected to boost growth of the market worldwide over the forecast period. According to Vanderbilt-Ingram Cancer Center report, 10% and 35% of NSCLC patients in U.S. and East Asia, respectively, have tumor associated with EGFR mutations. Mutation in EGFR gene occurs in EGFR exons 18–21, which encodes a part of EGFR kinase protein. These mutations are usually heterozygous, where the mutant allele exhibits gene amplification. Around 90% of these mutations are due to exon 19 deletion or exon 21 L858R point mutation. According to Annals of Oncology, EGFR mutation testing is required prior to first-line therapy in 81% of the stage IIIb/IV NSCLC patients. Thus, increasing demand for the EGFR mutation test and rising incidence of NSCLC patients with EGFR mutation are expected to drive growth of the global EGFR mutation test market over the forecast period.

Increased focus on formation of research consortiums on testing techniques is leading to rise in awareness levels and increased adoption of such methods. In addition, increasing adoption of technique by consumers and availability of wide range of kits, with new and advanced drugs, for EGFR detection are some of the factors expected to fuel growth of the global EGFR mutation test market. Availability of different methods to detect the abnormalities in the cell and identify the mutation.

A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/12535

However, less focus on developing techniques for detection tests by companies due to less profitability and lack of awareness among physicians are some of the factors that could hamper growth of the global EGFR mutation test market.

Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/12535

On the basis of region, EGFR mutation test market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America dominates the global EGFR mutation test market due to high prevalence of patients with EGFR mutation and large number of facilities for cancer treatment. However, growth in Middle East and African regions is expected to increase significantly over the forecast period due to increase in incidence of EGFR .

Roche Pharmaceuticals dominates the global EGFR mutation test market.

To Know About Latest Report Click Here: http://www.persistencemarketresearch.com/market-research/egfr-mutation-test-market.asp

About Us 
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
 PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release EGFR Mutation Test Market Estimated to Flourish by 2016 – 2024 here

News-ID: 612756 • Views:

More Releases from Persistence Market Research

Prepackaged Medical Kits & Trays Market Set to Surge to US$47.9 Billion by 2032, Reveals Latest Study
Prepackaged Medical Kits & Trays Market Set to Surge to US$47.9 Billion by 2032, …
The prepackaged medical kits & trays market plays a critical role in enhancing healthcare efficiency, reducing procedure time, and ensuring patient safety. These kits and trays are extensively used across hospitals, clinics, diagnostic centers, and surgical centers, offering ready-to-use medical instruments, consumables, and devices for specific procedures. They streamline workflow, minimize the risk of contamination, and support compliance with stringent regulatory standards. According to the latest study, the global prepackaged
Endodontic Reparative Cement Market Set to Reach US$512.2 Mn by 2032 at 4.7% CAGR
Endodontic Reparative Cement Market Set to Reach US$512.2 Mn by 2032 at 4.7% CAG …
The endodontic reparative cement market plays a crucial role in dental care by enhancing the success of root canal treatments, apexification procedures, and pulp capping. These cements are extensively used by dental professionals for repairing root perforations, sealing retrograde fillings, and promoting periapical healing. They improve biocompatibility, sealing ability, and antimicrobial properties, making them indispensable in modern endodontic procedures. According to the latest study, the global endodontic reparative cement market
Sleep Aids Market to Reach US$41.8 Bn by 2032 with 4.3% CAGR, Says Persistence Market Research
Sleep Aids Market to Reach US$41.8 Bn by 2032 with 4.3% CAGR, Says Persistence M …
The global sleep aids market is poised for substantial growth in the coming years. As of 2025, the market size is projected to be valued at approximately USD 31 billion and is expected to reach USD 41.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% during the forecast period from 2025 to 2032. This growth is primarily driven by the rising prevalence of sleep disorders, an
Europe Dental Imaging Equipment Market Set to Surge to US$1.67 Bn by 2032 at 6.6% CAGR
Europe Dental Imaging Equipment Market Set to Surge to US$1.67 Bn by 2032 at 6.6 …
The Europe dental imaging equipment market plays a pivotal role in enhancing diagnostic accuracy, treatment planning, and patient care in dental practices. These imaging systems are widely used across dental clinics, hospitals, and diagnostic centers to provide high-resolution, precise images of teeth, jawbones, and surrounding tissues. With advancements in digital technology, dental imaging equipment now offers reduced radiation exposure, 3D imaging capabilities, and improved workflow efficiency, making them indispensable in

All 5 Releases


More Releases for EGFR

Epidermal Growth Factor Receptor (EGFR) Inhibitor Market: Growth Trends to Watch
Epidermal Growth Factor Receptor (EGFR) Inhibitor Market valued at USD X.X Billion in 2024 and is projected to reach USD X.X Billion by 2032, growing at a CAGR of X.X% from 2025 to 2032. What is the Epidermal Growth Factor Receptor (EGFR) Inhibitor Market and Why is It Significant? The Epidermal Growth Factor Receptor (EGFR) inhibitor market focuses on therapies that target the EGFR pathway, which plays a critical role in the
EGFR Inhibitors Market to Reach USD 16 Billion by 2034
Targeting Lung Cancer with Precision: EGFR Inhibitors Market to Reach USD 16 Billion by 2034 The global burden of non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, continues to rise, and so does the demand for more targeted, effective, and personalized treatments. Epidermal Growth Factor Receptor (EGFR) inhibitors have emerged as a game-changing class of targeted therapies that address EGFR gene mutations-common drivers in NSCLC patients, especially
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Growth 2025: Trends, Consu …
The EGFR non-small cell lung cancer (EGFR + NSCLC) market is estimated to be valued at USD 4.65 Bn in 2025 and is expected to reach USD 7.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The Latest published market study on EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market report provides an overview of the current market dynamics as well
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Clinical Trials 2024: EMA, PDMA, …
(New York, United States) As per DelveInsight's assessment, globally, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline constitutes 30+ key companies continuously working towards developing 30+ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the
EGFR Non-Small Cell Lung Cancer Pipeline Report 2024
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage,
Epidermal Growth Factor Receptor (EGFR) Antibodies 2015 Market Research Report
The epidermal growth factor receptor (EGFR) is defined as a transmembrane tyrosine kinase receptor involved in the survival and proliferation of the cancerous cells. Any kind of mutations affecting these EFGR receptors or activity could results in cancer. Mutations lead to over-expresion resulting in large number of cancer, including lung cancer, anal cancer and glioblastoma multiforme. EGFR receptors are the first molecule target against which monoclonal antibodies (mAb) have been